The estimated Net Worth of Michael Milos Thornton is at least $899 millier dollars as of 18 May 2023. Mr. Thornton owns over 15,000 units of ENDRA Life Sciences Inc stock worth over $8,535 and over the last 8 years he sold NDRA stock worth over $82,350. In addition, he makes $808,610 as Chief Technology Officer at ENDRA Life Sciences Inc.
Michael has made over 6 trades of the ENDRA Life Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of NDRA stock worth $24,750 on 18 May 2023.
The largest trade he's ever made was selling 33,750 units of ENDRA Life Sciences Inc stock on 29 March 2021 worth over $82,350. On average, Michael trades about 6,592 units every 77 days since 2017. As of 18 May 2023 he still owns at least 34,139 units of ENDRA Life Sciences Inc stock.
You can see the complete history of Mr. Thornton stock trades at the bottom of the page.
Michael Milos Thornton serves as Chief Technology Officer of the Company. Mr. Thornton was a founder and President of Enhanced Vision Systems Corp., or EVS, a developer and supplier of medical imaging equipment to the pharmaceutical, biotech, and academic sectors. In 2002, EVS was acquired by General Electric Company and was integrated into the Functional and Molecular Imaging business unit of GE Medical Systems (now GE Healthcare, a subsidiary of General Electric Company). Following the acquisition of EVS by GE Medical Systems, Mr. Thornton held a number of positions at GE Healthcare, including Sales Manager, Global Product Manager, and Site Leader. He was a member of the leadership team that expanded the pre-clinical imaging business to include: computed tomography, optical, and positron emission tomography imaging technologies, with global market reach. He is also a founder of Volumetrics Medical Corp., a developer and manufacturer of quality assurance devices for diagnostic imaging. Prior to founding EVS, Mr. Thornton developed medical imaging related technologies at the Robarts Research Institute (London, Ontario, Canada) for which he obtained an MSc in Electrical Engineering from the University of Western Ontario. Mr. Thornton also holds a BASc in Electrical Engineering from the University of Toronto and is a member of the American Association of Physicists in Medicine.
As the Chief Technology Officer of ENDRA Life Sciences Inc, the total compensation of Michael Thornton at ENDRA Life Sciences Inc is $808,610. There are 1 executives at ENDRA Life Sciences Inc getting paid more, with Francois Michelon having the highest compensation of $978,776.
Michael Thornton is 51, he's been the Chief Technology Officer of ENDRA Life Sciences Inc since 2007. There are 8 older and 1 younger executives at ENDRA Life Sciences Inc. The oldest executive at ENDRA Life Sciences Inc is Michael Harsh, 65, who is the Independent Director.
Michael's mailing address filed with the SEC is 3600 GREEN COURT, SUITE 350, , ANN ARBOR, MI, 48105.
Over the last 8 years, insiders at ENDRA Life Sciences Inc have traded over $893,199 worth of ENDRA Life Sciences Inc stock and bought 413,648 units worth $301,877 . The most active insiders traders include Group Ag Ubs, Capital Advisors, Llc Conra... et Alexander Y Tokman. On average, ENDRA Life Sciences Inc executives and independent directors trade stock every 61 days with the average trade being worth of $5,922. The most recent stock trade was executed by Group Ag Ubs on 27 August 2024, trading 3,715 units of NDRA stock currently worth $2,043.
endra life sciences is bringing new capabilities to ultrasound. our photo-acoustic solutions help medical researchers screen and modify disease models with unparalleled quality and speed. we’re proud to have a global installed base of leading institutions using our nexus-128 system, the only 3d imaging solution for imaging anatomy, physiology and labeled molecular targets. the nexus 128 is a preclinical photoacoustic computed tomography (ct) scanner for small animal imaging. the system is used for simple, fast, non-invasive quantification of physiological parameters such as tumor vasculature without ionizing radiation. the fully-3d imaging technology used by the nexus 128 provides increased sensitivity compared to slice-based scanners, and dynamic (4-d) photoacoustic ct scans allow for applications such as quantification of probe uptake. the nexus 128 is currently being used by top imaging laboratories around the globe.
ENDRA Life Sciences Inc executives and other stock owners filed with the SEC include: